FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas

Journal Article · 01 January 2010 · Sarcoma

DOI: https://doi.org/10.1155/2010/143540 · OSTI ID:1198465

Benz, Matthias R. ^[1]; Czernin, Johannes ^[1]; Tap, William D. ^[2]; Eckardt, Jeffrey J. ^[3]; Seeger, Leanne L. ^[4]; Allen-Auerbach, Martin S. ^[1]; Dry, Sarah M. ^[5]; Phelps, Michael E. ^[1]; Weber, Wolfgang A. ^[6]; Eilber, Fritz C. ^[7]

---

1. Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
2. Division of Medical Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
3. Department of Orthopedic Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
4. Department of Radiology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
5. Department of Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA
6. Abteilung Nuklearmedizin, University of Freiburg, 79106 Freiburg, Germany
7. Ahmanson Biological Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA, Division of Surgical Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1782, USA

Purpose . The aim of this study was to prospectively evaluate whether FDG-PET allows an accurate assessment of histopathologic response to neoadjuvant treatment in adult patients with primary bone sarcomas. Methods . Twelve consecutive patients with resectable, primary high grade bone sarcomas were enrolled prospectively. FDG-PET/CT imaging was performed prior to the initiation and after completion of neoadjuvant treatment. Imaging findings were correlated with histopathologic response. Results . Histopathologic responders showed significantly more pronounced decreases in tumor FDG-SUVmax from baseline to late follow up than non-responders ( $64\pm 19$ % versus $29\pm 30$ %, resp.; $P=.03$ ). Using a 60% decrease in tumor FDG-uptake as a threshold for metabolic response correctly classified 3 of 4 histopathologic responders and 7 of 8 histopathologic non-responders as metabolic responders and non-responders, respectively (sensitivity, 75%; specificity, 88%). Conclusion . These results suggest that changes in FDG-SUVmax at the end of neoadjuvant treatment can identify histopathologic responders and non-responders in adult primary bone sarcoma patients.

• Sponsoring Organization: USDOE
• Grant/Contract Number: FG02-06ER64249
• OSTI ID: 1198465
• Journal Information: Sarcoma, Journal Name: Sarcoma Vol. 2010; ISSN 1357-714X
• Publisher: Hindawi Publishing CorporationCopyright Statement
• Country of Publication: United States
• Language: English